⌘+K

Pulse Explore Communities Researchers Journals

Home Communities Explore

September 2, 2025Open Access

Supplementary Figure S5 from Unraveling Relatlimab-Specific Biology Using Biomarker Analyses in Patients with Advanced Melanoma in RELATIVITY-047

Evan J. Lipson Sonia Dolfi Hao Tang Hussein A. Tawbi Francisco Medina-Soto Erika Castillo Gutiérrez Piotr Rutkowski Helen Gogas E. de Eusebio Murillo Paolo A. Ascierto Keyur Desai Michele Maio Korey Demers Antonella Mazzei Sarah Keidel Karen Miller-Moslin Jia Xin Yu F. Stephen Hodi Dirk Schadendorf Georgina V. Long Charlie Garnett‐Benson

View Full Paper

Ask AI

Bookmark

Share

Key Points

Biomarker analysis reveals key CD8 characteristics in the tumor microenvironment, and highlights immune response dynamics.
Important findings include detailed profiles of CD8 T cells in advancing melanoma, emphasizing immune interactions.
Assessment of CD8 characterization focuses on tumor microenvironments and provides insights into patient responses to treatment.
These results suggest potential pathways for enhancing immune therapies, pushing for further studies in advanced melanoma.

No abstract yet

We only have this paper's title and publication details.

Read it at the source→

Ask about this paper

Answers are grounded in this paper and cite their sources.

Ask your own question…

Implication

Biomarker analysis reveals CD8 characteristics in tumor microenvironments of melanoma patients, indicating immune response.

Abstract

CD8 characterization in the TME.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Lipson et al. (2025) studied this question.

synapsesocial.com/papers/68c182609b7b07f3a060f5b7 https://doi.org/10.1158/1078-0432.30029455

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Supplementary Figure S7 from Unraveling Relatlimab-Specific Biology Using Biomarker Analyses in Patients with Advanced Melanoma in RELATIVITY-0472025
2Supplementary Figure S1 from Unraveling Relatlimab-Specific Biology Using Biomarker Analyses in Patients with Advanced Melanoma in RELATIVITY-0472025
3Supplementary Figure S4 from Unraveling Relatlimab-Specific Biology Using Biomarker Analyses in Patients with Advanced Melanoma in RELATIVITY-0472025
4Supplementary Figure S8 from Unraveling Relatlimab-Specific Biology Using Biomarker Analyses in Patients with Advanced Melanoma in RELATIVITY-0472025
5Supplementary Figure S6 from Unraveling Relatlimab-Specific Biology Using Biomarker Analyses in Patients with Advanced Melanoma in RELATIVITY-0472025

Supplementary Figure S3 from Unraveling Relatlimab-Specific Biology Using Biomarker Analyses in Patients with Advanced Melanoma in RELATIVITY-0472025
Supplementary Figure S2 from Unraveling Relatlimab-Specific Biology Using Biomarker Analyses in Patients with Advanced Melanoma in RELATIVITY-0472025
Supplementary Figure 6 from Nivolumab and Relatlimab for the Treatment of Patients with Unresectable or Metastatic Mismatch Repair–Proficient Colorectal Cancer2025